Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 221,489
  • Shares Outstanding, K 38,587
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,600 K
  • EBIT $ -60 M
  • EBITDA $ -60 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 90.58% (-34.93%)
  • Historical Volatility 118.63%
  • IV Percentile 1%
  • IV Rank 1.53%
  • IV High 633.46% on 11/10/25
  • IV Low 82.13% on 02/03/25
  • Expected Move (DTE 8) 0.72 (12.59%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,223
  • Volume Avg (30-Day) 433
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 6,821
  • Open Int (30-Day) 5,212
  • Expected Range 5.02 to 6.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.39
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.50 +27.56%
on 11/11/25
7.82 -26.60%
on 11/24/25
+1.21 (+26.71%)
since 11/10/25
3-Month
3.02 +90.07%
on 09/17/25
7.82 -26.60%
on 11/24/25
+2.63 (+84.57%)
since 09/10/25
52-Week
2.77 +107.22%
on 07/02/25
7.82 -26.60%
on 11/24/25
-0.51 (-8.16%)
since 12/10/24

Most Recent Stories

More News
Protara Announces Closing of $75 Million Public Offering

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...

TARA : 5.74 (unch)
Protara Announces Pricing of $75 Million Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...

TARA : 5.74 (unch)
Protara Announces Proposed Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...

TARA : 5.74 (unch)
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the...

TARA : 5.74 (unch)
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

TARA : 5.74 (unch)
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical success Clinical success achieved with one or two doses of TARA-002...

TARA : 5.74 (unch)
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

TARA : 5.74 (unch)
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today...

TARA : 5.74 (unch)
Protara Therapeutics: Q3 Earnings Snapshot

Protara Therapeutics: Q3 Earnings Snapshot

TARA : 5.74 (unch)
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 Expect to present interim analysis from approximately 25 six-month...

TARA : 5.74 (unch)

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 6.09
2nd Resistance Point 5.95
1st Resistance Point 5.84
Last Price 5.74
1st Support Level 5.59
2nd Support Level 5.45
3rd Support Level 5.34

See More

52-Week High 7.82
Fibonacci 61.8% 5.89
Last Price 5.74
Fibonacci 50% 5.30
Fibonacci 38.2% 4.70
52-Week Low 2.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar